Drug Database
AN

antithrombin III

✓ Approved

GC Biopharma · SERPINC1 · Cell-based Therapies

What is antithrombin III?

antithrombin III is a cell-based therapies developed by GC Biopharma. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyGC Biopharma
Drug ClassCell-based Therapies
Molecular TargetSERPINC1
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, GC Biopharma

Mechanism of Action

Molecular Targets

antithrombin III acts on 1 molecular target:

SERPINC1serpin family C member 1 (ATIII, AT3D)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

antithrombin III is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved

Related Research Articles

PubMedEuropean radiology2026-09-20

Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging.

Wang Guangsong G, Shi Dafa D, Guo Qiu Q, Wang Rui R et al.

To identify robust tumor habitat subregions using pre-treatment MRI and assess the prognostic value of the resulting phenotypes for recurrence risk stratification in stages II-III breast cancer. This multicenter retrospective study included 842 women with stages II-III breast cancer who received pre-treatment MRI scans and subsequent surgical resection from three centers (multicenter discovery cohort: n = 415; external test cohort: n = 427). An unsupervised clustering-based habitat characterization framework was applied to delineate tumor subregions and identify distinct structure habitat phenotypes (SH-phenotypes). Recurrence-free survival (RFS) was evaluated using Kaplan-Meier analysis and multivariate Cox regression. Fine-Gray competing risk regression was additionally used to account for death as a competing event. Two structural subregions (central and peripheral) with unique radiomic patterns and three SH-phenotypes with distinct RFS were identified in the discovery cohort and validated in the test cohort (log-rank p < 0.001 for both). The SH-phenotypes remained independent prognostic predictors after adjustment for tumor size, nodal involvement, clinical subtype, pathological grade, and patient age [test cohort: SH-phenotype 2 vs 1, hazard ratio (HR) = 2.29, p = 0.048; SH-phenotype 3 vs 1, HR = 3.45, p = 0.006]. Similar results were obtained in the competing risk regression analysis. Two structural habitat subregions were identified, and the derived SH-phenotypes provide additional prognostic value beyond clinicopathological factors for recurrence risk stratification in stages II-III breast cancer. Question Precise evaluation of recurrence risk is crucial for tailoring therapy for stages II-III breast cancer, but it remains challenging with classical clinicopathological factors. Findings Pre-treatment MRI-based SH analysis identified three phenotypes with distinct RFS and recurrence cumulative incidence, independent of clinicopathological factors. Clinical relevance The clinical utility of this phenotyping lies in its role as an adjunct to classical clinicopathological factors, enhancing recurrence risk stratification for optimized treatment planning in stages II-III breast cancer.

PMID 42763333
Read full article →
PubMedOncoTargets and therapy2026-09-20

ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions.

Al-Shamsi Humaid O HO, Rafii Saeed S, Tirmazy Syed Hammad Hassan SHH, Mukherji Deborah D et al.

Circulating tumor DNA (ctDNA) is an increasingly important biomarker for molecular residual disease (MRD) after curative-intent treatment of colorectal cancer (CRC), but its prognostic value must be distinguished from proven clinical utility. This structured narrative review synthesizes evidence from PubMed/MEDLINE, Embase, ClinicalTrials.gov, and major oncology conference proceedings, covering stage I-III CRC and selected patients with resected or ablated oligometastatic stage IV disease. We review tumor-informed and tumor-agnostic assay strategies, postoperative sampling, serial versus landmark testing, low-shedding disease, clonal hematopoiesis, and major prospective and randomized studies. Postoperative ctDNA positivity consistently identifies patients at substantially increased risk of recurrence, while serial ctDNA dynamics provide additional prognostic information. In stage II colon cancer, the randomized DYNAMIC trial showed that a ctDNA-guided strategy reduced adjuvant chemotherapy use without compromising long-term recurrence outcomes. By contrast, DYNAMIC-III did not establish non-inferiority for ctDNA-guided de-escalation and showed no recurrence-free survival benefit from conventional chemotherapy escalation in ctDNA-positive stage III disease. The Phase III ALTAIR trial likewise did not meet its pre specified primary disease-free survival endpoint for treatment of molecular relapse with trifluridine/tipiracil. Current professional guidance therefore supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-based indications or clinical trials. Future progress requires harmonized assays, randomized demonstration of outcome benefit, and prospective validation of integrated ctDNA, pathology, transcriptomic, and AI-derived risk models.

PMID 42763649
Read full article →
PubMedArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association2026-09-20

Labral Repair and Reconstruction Yield Comparable Patient-Reported Outcomes at Short- to Mid-Term Follow-Up During Primary Hip Arthroscopy: A Systematic Review.

Messer Kyle P KP, Pinchok Alicia R AR, Hernandez Evan J EJ, Dhillon Jaydeep J et al.

To systematically review and compare clinical outcomes and survivorship of labral repair versus labral reconstruction during primary hip arthroscopy. A search of PubMed, the Cochrane Library, and Embase databases was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Comparative clinical studies investigating labral repair versus reconstruction during primary hip arthroscopy were included. Outcomes assessed included patient-reported outcomes (PROs), rate of revision hip arthroscopy, and conversion to total hip arthroplasty. Six Level III studies met inclusion criteria (1628 labral repairs, 679 reconstructions). Mean age at surgery ranged from 29.9 to 48.6 years (repair) and 34.6 to 48.1 years (reconstruction). Mean follow-up ranged from 2.0 to 5.8 years. All studies showed significant within-group improvements in PROs with minimal clinically important difference and patient acceptable symptomatic state achievement rates exceeding 70% in both groups, with no significant between-group differences. Two studies found no significant differences in postoperative PROs or magnitude of improvement between groups. Conversely, 2 studies showed greater mean PRO improvement in the reconstruction group, including patients aged ≥40 years in 1 study, while 1 study reported higher adjusted postoperative PROs for labral repair. Four studies showed no significant differences in revision rates, but 1 reported a lower total hip arthroplasty conversion rate after labral repair, and 1 reported a lower failure rate with reconstruction in patients aged ≥40 years. Both labral repair and reconstruction show significant improvements in PROs at short- to mid-term follow-up, with comparable achievement of minimal clinically important difference and patient acceptable symptomatic state thresholds. However, evidence suggests that labral repair yields lower rates of conversion to total hip arthroplasty, whereas reconstruction offers better clinical outcomes and lower failure rates in patients aged ≥40. Consequently, the optimal surgical approach should be individualized based on patient age, intraoperative assessment of tissue quality, and overall joint pathology. Level III, systematic review of Level III studies.

PMID 42763809
Read full article →
PubMedCureus2026-09-20

Implant-Supported Rehabilitation Following Endodontic Failure in a Patient Classified as American Society of Anesthesiologists (ASA) Physical Status III With Chronic Post-Stroke Hemiplegia: A Multidisciplinary Dental Case Report.

Arenas Perez Nayibe N

Patients with chronic neurological disabilities frequently present significant challenges in dental treatment due to functional limitations, impaired oral hygiene, and concerns regarding medical risk. These challenges often result in delayed care or refusal of treatment, particularly when surgical procedures and implant rehabilitation are required. This report describes the multidisciplinary dental management of a 76-year-old male patient classified as American Society of Anesthesiologists (ASA) Physical Status III with a history of ischemic cerebrovascular accident resulting in chronic right-sided hemiplegia, facial paralysis, wheelchair dependence, and reduced ability to perform oral hygiene independently. The patient presented on an emergency basis with severe pain associated with a previously endodontically treated maxillary right second premolar. Clinical and radiographic evaluation, including cone-beam computed tomography (CBCT), revealed persistent periapical infection consistent with endodontic failure. Given the patient's medical history, a comprehensive hospital-based medical evaluation and neurological clearance were obtained prior to treatment. The patient's poor oral hygiene status was addressed through caregiver-assisted oral hygiene instruction, professional dental cleaning, and infection control measures. Following medical approval, the affected tooth was extracted, and alveolar ridge preservation was performed using particulate bone graft material and a resorbable collagen membrane. After a six-month healing period, implant placement was completed using CBCT-guided treatment planning. Three months later, a definitive screw-retained implant-supported crown was fabricated using a digital workflow and successfully delivered. The patient experienced complete resolution of pain, restoration of masticatory function, and improvement in overall quality of life. This case highlights the importance of multidisciplinary dental management, advanced imaging, medical clearance, and caregiver involvement when treating medically stable ASA III patients with chronic post-stroke disabilities. The outcome observed in this carefully selected patient suggests that implant-supported rehabilitation may be successfully performed when appropriate individualized medical assessment, maintenance, and long-term oral hygiene support are available.

PMID 42763609
Read full article →
PubMedArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association2026-09-20

Bone Marrow Aspirate Augmentation Reduces Reoperation Rates After Osteochondral Allograft Transplantation of the Knee: A Systematic Review.

Thamrongskulsiri Napatpong N, Morgan Jacob T JT, Casanova Felipe F, Moews Logan D LD et al.

To systematically review the clinical, radiographic, and patient-reported outcomes of osteochondral allograft (OCA) transplantation with versus without bone marrow aspirate (BMA) augmentation for the treatment of knee cartilage defects. A comprehensive search was performed according to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Comparative clinical studies assessing OCA with and without BMA were included. Two reviewers independently performed screening, data extraction, and methodological quality assessment using the Cochrane Risk of Bias Tool 2.0 for randomized trials and the Methodological Index for Non-Randomized Studies for nonrandomized studies. Four studies (3 Level III, 1 Level I) involving 165 knees met the inclusion criteria. The mean follow-up duration across studies ranged from 5.5 to 18.0 months. Across 2 comparative studies, BMA augmentation was associated with fewer reoperations (2.4% vs 21.9%) compared with non-BMA augmentation. Radiographic findings were heterogeneous: 1 study showed earlier integration and reduced sclerosis with BMA at 6 months, whereas 2 magnetic resonance imaging-based studies showed no differences in OCA Magnetic Resonance Imaging Scoring System scores. Computed tomography assessment in 1 trial found increased small cysts but a trend toward fewer large cysts in BMA-treated grafts. Patient-reported outcomes from 1 study showed no significant differences in International Knee Documentation Committee or Knee injury and Osteoarthritis Outcome Score for Joint Replacement scores between groups, although achievement of the Knee injury and Osteoarthritis Outcome Score for Joint Replacement minimal clinically important difference favored the BMA cohort (88% vs 55%; P = .076). OCA transplantation augmented with BMA is associated with significantly lower reoperation rates compared with nonaugmented transplantation. Although short-term radiographic data show improved early subchondral remodeling, these findings are not consistently corroborated by magnetic resonance imaging-based scores. Level III, systematic review of Level I and III studies.

PMID 42763432
Read full article →
PubMedCureus2026-09-20

GLT6D1 rs1537415 G Allele and Advanced Periodontitis: A Meta-Analysis.

Karaoulas Theofanis A TA, Xirouchakis Christoforos C, Neophytou Chariklia C, Fragkioudakis Ioannis I

This meta-analysis aimed to evaluate the association of the GLT6D1 rs1537415 G allele with susceptibility to periodontitis stage III/IV, grade B or C. Adhering to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, three eligible studies were identified through comprehensive searches of PubMed, Web of Science, and Scopus. Data from 2,185 participants (668 cases and 1,517 controls) were analyzed using random-effects models to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity was assessed using Chi² and I² statistics. Formal testing for publication bias was precluded by the small number of studies (n = 3). The meta-analysis demonstrated a significant association between the rs1537415 G allele and severe periodontitis, with a pooled OR of 1.58 (95% CI: 1.28-1.95). Subgroup analyses showed consistent associations in European and Sudanese populations, whereas no significant association was observed in the Brazilian cohort. Sensitivity analysis excluding the largest Genome-Wide Association Study (GWAS) attenuated the association to a non-significant level (OR = 1.37; 95% CI: 0.87 to 2.16), indicating that a single study largely drove the overall effect; the pooled estimate should therefore be interpreted with caution. The GLT6D1 rs1537415 G allele may represent a genetic risk factor for severe periodontal diseases, particularly stage III/IV and grade B/C, suggesting a possible role in immune modulation. Further research involving larger, multi-ethnic cohorts is crucial to validate these associations and explore gene-environment interactions.

PMID 42763709
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about antithrombin III